Clinical Medicine · 2021 · 337 citations · 14 references
PharmacyPharmacotherapySurgeryClinical PharmacologyGastrointestinal PharmacotherapyImmunotherapyCrohn Disease PharmacotherapyGastrointestinal InflammationInflammatory Bowel DiseaseInflammatory Bowel Disease CareInflammatory Disease PharmacotherapyUlcerative Colitis PharmacotherapyAltered Mucosal HealingBest Medical TherapyBiologic Therapy ManagementClinical RemissionImmunosuppressive CompoundsInflammatory Bowel Disease TherapyMucosal Healing ResponsePost-surgical Mucosal Healing
Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing and improvement in a patient's quality of life. 5-aminosalicylate acid medications remain the first-line treatment for mild to moderate disease. In the event of suboptimal response to these medications, escalation to immunosuppressive medications and biologics may be necessary. Importantly, despite best medical therapy, surgery may be required in a proportion of patients. The future will likely see an array of new therapeutic options for those with ulcerative colitis with the potential for a more personalised treatment approach.
14
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.9K citations · Full text
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn, Chinyu Su, Bruce E. Sands et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
Bruce E. Sands, William J. Sandborn, Remo Panaccione et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text
Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity
Simon Travis, Dan Schnell, Piotr Krzeski et al. · Gastroenterology · 2013 · 446 citations · Full text